MktsMarkets

Cue Biopharma, Inc.
NASDAQ: CUEKey statistics
CUE News
Stories mentioning CUE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 5,686 | 21,942 | 2,149 | 2,954 | 421.00 | 1,576 | 3,336 | 2,658 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 6,897 | 16,532 | 4,754 | 7,910 | 8,547 | 7,185 | 9,381 | 9,530 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 11,039 | 19,965 | 9,744 | 11,589 | 12,720 | 11,210 | 12,151 | 13,041 |
| Operating Income (Loss) | (5,353) | 1,977 | (7,595) | (8,635) | (12,299) | (9,634) | (8,815) | (10,383) |
| Interest Income | ||||||||
| Interest Expense | 100.00 | |||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (5,178) | 1,585 | (7,448) | (8,482) | (12,257) | (9,496) | (8,660) | (10,171) |
| Earnings Per Share (Basic) | (1.08) | 0.02 | (0.07) | (0.09) | (4.95) | (0.17) | (0.17) | (0.20) |
| Earnings Per Share (Diluted) | (1.08) | 0.02 | (0.07) | (0.09) | (4.95) | (0.17) | (0.17) | (0.20) |
| Weighted Average Shares Outstanding (Basic) | 4,807 | 94,732 | 100,869 | 95,459 | 2,475 | 56,328 | 51,230 | 50,175 |
| Weighted Average Shares Outstanding (Diluted) | 4,807 | 94,732 | 100,869 | 95,459 | 2,475 | 56,328 | 51,230 | 50,175 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CUE
Cue Biopharma, Inc. (NASDAQ: CUE) is a stock listed on the Nasdaq Stock Market under the ticker symbol CUE. It last traded at $7.43 (Nov 17, 2026, 11:29 AM ET), down 47.3% on the day. That gives Cue Biopharma a market capitalisation of $102.0M.
Over the past 52 weeks CUE has traded between $4.97 and $45.50.
Revenue for the quarter ended Mar 31, 2026 was $5.7M; a net loss of $5.2M. Revenue was up 1251% from $421.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $5.7M | -$5.2M | -91.1% |
| Dec 31, 2025 | $21.9M | $1.6M | 7.2% |
| Sep 30, 2025 | $2.1M | -$7.4M | -346.6% |
| Jun 30, 2025 | $3.0M | -$8.5M | -287.1% |
From Cue Biopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…